Evaluation of Patiromer in Heart Failure Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
HyperkalemiaHeart Failure
Interventions
DRUG

patiromer

Active investigational drug

DRUG

placebo

placebo

Trial Locations (33)

11768

Investigator Site 005, Northport

12008

Investigator Site 104, Prague

14021

Investigator Site 103, Prague

14215

Investigator Site 020, Buffalo

33176

Investigator Site 029, Miami

33952

Investigator Site 031, Port Charlotte

37075

Investigator Site 201, Göttingen

43210

Investigator Site 022, Columbus

49023

Investigator Site 507, Dnipropetrovsk

55417

Investigator Site 018, Minneapolis

61018

Investigator Site 502, Kharkiv

61176

Investigator Site 509, Kharkiv

61606

Investigator Site 009, Peoria

62500

Investigator Site 102, Brno

69120

Investigator Site 202, Heidelberg

75216

Investigator Site 001, Dallas

84124

Investigator Site 019, Salt Lake City

111020

Investigator Site 406, Moscow

111539

Investigator Site 402, Moscow

129301

Investigator Site 403, Moscow

197341

Investigator Site 404, Saint Petersburg

198205

Investigator Site 412, Saint Petersburg

199106

Investigator Site 405, Saint Petersburg

650002

Investigator Site 407, Kemerovo

656099

Investigator Site 409, Barnaul

0102

Investigator Site 605, Tbilisi

0159

Investigator Site 602, Tbilisi

0164

Investigator Site 604, Tbilisi

0179

Investigator Site 603, Tbilisi

02637

Investigator Site 305, Warsaw

03680

Investigator Site 504, Kiev

Investigator Site 506, Kiev

04114

Investigator Site 501, Kiev

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Relypsa, Inc.

INDUSTRY